Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
sulphonylurea · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| metformin | DRUG | - |
| sulphonylurea | DRUG | - |
| Avandamet | DRUG | - |
Inclusion criteria: * Body mass index \> or = to 25 kg/m2. * HbA1c \> or =7% and \< or =10% at screening. * FPG \> or = 7.0mmol/L (126mg/dL) at visit 2. * Receiving at least 0.85g of metformin at constant dose(s) for at least 8 weeks prior to visit 1a. * Female subjects must be postmenopausal or us...
Sulphonylurea is used for the treatment of non-insulin-dependent diabetes mellitus, also known as type 2 diabetes. It is a small molecule therapeutic being developed by GSK plc for this metabolic condition.
Sulphonylurea is being developed by GSK plc, a pharmaceutical company listed on the stock exchange under the ticker GSK. The drug is intended for the treatment of non-insulin-dependent diabetes mellitus.
Sulphonylurea is in Phase 3 clinical development. It is an investigational drug for non-insulin-dependent diabetes mellitus and has not been approved for marketing. One Phase 3 trial has been completed.
Sulphonylurea has been studied in a Phase 3 clinical trial with the identifier NCT00359112. The trial, titled 'AVANDAMET Versus Metformin And Sulphonylurea In People With Poorly Controlled Type 2 Diabetes', enrolled 544 participants and has been completed.
Sulphonylurea is not the same as AVANDAMET. The clinical trial NCT00359112 compared AVANDAMET against a combination of metformin and sulphonylurea, indicating that sulphonylurea is a separate treatment evaluated in the study.